Skip to content

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study – Pfizer

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study  PfizerPfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%  CNBCPfizer says antiviral pill cuts risk of severe COVID-19 by 89%  Yahoo MoneyCBSN Minnesota’s Morning Update: Nov. 5, 2021  WCCO – CBS MinnesotaOctober jobs report smashes expectations  The Week Magazine

Leave a Reply

Your email address will not be published. Required fields are marked *